| Title |
Current management options for latent tuberculosis: a review
|
|---|---|
| Published in |
Infection and Drug Resistance, November 2012
|
| DOI | 10.2147/idr.s29180 |
| Pubmed ID | |
| Authors |
Brianna L Norton, David P Holland |
| Abstract |
Tuberculosis remains the world's second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the standard of care for decades, but its utility is impaired by poor completion rates. However, new, shorter-course regimens using rifamycins improve completion rates and are cost-saving compared with standard isoniazid monotherapy. We review the currently available therapies for latent tuberculosis infection and their toxicities and include a brief economic comparison of the different regimens. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 72 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 22% |
| Researcher | 12 | 16% |
| Student > Ph. D. Student | 11 | 15% |
| Student > Postgraduate | 6 | 8% |
| Student > Bachelor | 5 | 7% |
| Other | 13 | 18% |
| Unknown | 11 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 39% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 11% |
| Agricultural and Biological Sciences | 8 | 11% |
| Biochemistry, Genetics and Molecular Biology | 6 | 8% |
| Immunology and Microbiology | 4 | 5% |
| Other | 4 | 5% |
| Unknown | 15 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2012.
All research outputs
#15,256,901
of 22,687,320 outputs
Outputs from Infection and Drug Resistance
#697
of 1,612 outputs
Outputs of similar age
#116,283
of 184,139 outputs
Outputs of similar age from Infection and Drug Resistance
#2
of 2 outputs
Altmetric has tracked 22,687,320 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,612 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 184,139 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.